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Abstract
Rationale Experimental studies have investigated the effects
of chronic donepezil treatment on the behavioral deficits
elicited by reduced activity or the loss of cholinergic neurons
that occurs in aging or in models of dementia. However, few
studies have analyzed the effects of chronic donepezil
treatment on the cognitive functions of intact animals.
Objectives The cognitive functions of healthy young rats
treated chronically with the acetylcholinesterase inhibitor
donepezil were evaluated using a wide behavioral test battery.
Results Chronic treatment with donepezil ameliorated
memory functions and explorative strategies, speeded up
the acquisition of localizing knowledge, augmented respon-
siveness to the context, and reduced anxiety levels.
However, it did not affect spatial span, modify motivational
levels, or influence associative learning.
Conclusions The present findings show the specific profile
of donepezil action on cognitive functions in the presence
of unaltered cholinergic neurotransmission systems.
Keywords Acetylcholinesterase inhibitor . Donepezil .
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Introduction
Acetylcholine (ACh) is a pivotal neurotransmitter in learn-
ing, memory, and attentive functions (Giovannini et al. 1997;
Parent and Baxter 2004; Pepeu and Giovannini 2004).
Alteration of cholinergic neurons is one of the primary
pathological changes found in the brains of patients affected
by Alzheimer’s disease (AD; Birks and Flicker 2006). The
“cholinergic hypothesis” (Bartus et al. 1982; Bartus 2000;
Freo et al. 2002; Sarter et al. 2003; Phillis 2005), which
postulates that the age-related decline in cognition may be
correlated with reduced cerebral cholinergic function, has led
to the development of pro-cholinergic compounds, such as
acetylcholinesterase inhibitors (AChE-Is), which are able to
enhance cognitive functioning (Dawson and Iversen 1993;
Carey et al. 2001; Takada et al. 2003).
Donepezil is a second-generation AChE-I with fewer
side effects than earlier drugs of its class and it has a very
long half-life (about 72 h). Currently, it is the first-line
palliative treatment for improving cognitive functioning in
AD patients afflicted by mild to moderate degrees of
dementia (Rogers et al. 1998; Shigeta and Homma 2001;
Sugimoto 2001; Bontempi et al. 2003; Seltzer 2007;
Winstein et al. 2007). Furthermore, donepezil was reported
to increase frontal activity during a working memory task in
patients affected by mild cognitive impairment, and this
increase was related to improved cognition (Saykin et al.
2004). There are also reports that donepezil reversed
memory deficits in experimental models of learning and
memory (Cheng et al. 1996; Rupniak et al. 1997; Higgins et
Psychopharmacology
DOI 10.1007/s00213-008-1084-0
D. Cutuli : F. Foti : L. Mandolesi : P. D. Bartolo : F. Gelfo :
F. Federico : L. Petrosini
IRCCS Santa Lucia Foundation,
Rome, Italy
L. Mandolesi : F. Gelfo
University of Naples “Parthenope”,
Naples, Italy
D. Cutuli : F. Foti : P. D. Bartolo : L. Petrosini (*)
Department of Psychology, University of Rome “La Sapienza”,
Via dei Marsi 78,
00185 Rome, Italy
e-mail: laura.petrosini@uniroma1.it
F. Federico
University of Siena,
Siena, Italy
al. 2002; Tokita et al. 2002; van der Staay and Bourger
2005; Wise et al. 2007). Acute administration of donepezil
in experimental models of cholinergic deficits improved
performances in the radial arm maze (Ogura et al. 2000;
Wise et al. 2007), the Morris water maze (Spowart-
Manning and van der Staay 2005), in spatial and visual
recognition tasks (Kirkby et al. 1996; Poorheidari et al.
1998; Prickaerts et al. 2005), and in serial reaction time
tasks (Kirkby et al. 1996).
Some experimental studies have investigated the effects
of chronic donepezil treatment on the behavioral deficits
elicited by reduced activity or the loss of cholinergic
neurons that occurs in aging (Barnes et al. 2000; Hernandez
et al. 2006) or in models of dementia (Dong et al. 2005;
Yamada et al. 2005). In particular, in Tg2576 mice, an
experimental model of AD, donepezil had ameliorative
effects on memory-related deficits (Dong et al. 2005).
Furthermore, chronic donepezil administration improved
memory impairment induced by i.c.v. injections of strepto-
zotocin (Sonkusare et al. 2005). Thus, research has
addressed the influence of donepezil on the symptoms
provoked by altered cholinergic transmission. However,
very few studies have investigated the putative influence of
donepezil treatment on normal subjects. Acute donepezil-
treated normal mice exhibited an increased rate of spontane-
ous alternations compared with controls (Spowart-Manning
and van der Staay 2004). Moreover, acute donepezil
administration before a spatial test elicited memory enhanc-
ing effects in rodents (Wise et al. 2007). These experimental
data integrate a few human studies reporting the effects of
cholinergic stimulation in healthy adult subjects. Davis et al.
(1978) reported that acute physostigmine administration
enhances storage of information in long-term memory as
well as its retrieval, without alterations of short-term
memory. More recently, it has been demonstrated that
modulation of the cholinergic system by physostigmine
infusions improved working memory efficiency and reduced
activation of the cortical regions associated with working
memory (Furey et al. 2000). Furthermore, Sun et al. (1999)
reported improved memory and learning functions in
adolescent Chinese students following a 4-week administra-
tion of an AChE-I (huperzine-A). Recent studies in healthy
aircraft pilots reported beneficial effects on the retention of
complex tasks (flight simulator) after 30 days of donepezil
treatment (Yesavage et al. 2002; Mumenthaler et al. 2003).
However, the tasks were very complex and tapped a
combination of cognitive functions that were difficult to
distinguish. Moreover, Grön et al. (2005) reported the
selective enhancement of episodic memory performance in
healthy young subjects following 30 days of donepezil
treatment, suggesting that the hippocampal region is the
major target of cholinergic enhancement elicited by long-
term inhibition of AChE. Overall, these findings suggest that
AChE-Is, and donepezil in particular, may act as “cognition
enhancers” in normal subjects.
Based on these findings, we set out to assess the specific
effects of chronic donepezil treatment on unaltered cholin-
ergic neurotransmission systems. To this aim, healthy
young rats chronically treated with donepezil were evalu-
ated using a behavioral test battery that tapped different
cognitive functions.
Materials and methods
Animals
Twenty male Wistar rats (300–350 g) kept in standard
laboratory conditions (08:00–20:00 light, food and water ad
libitum) were used in the present experiments. The animals
were maintained according to the guidelines for ethical
conduct developed by the European Communities Council
Directive of 24 November 1986 (86/609/EEC) and ap-
proved by the Ethical Committee on animal experiments of
the University of Rome “La Sapienza”. Rats were randomly
assigned to two experimental groups: the treated group (D;
n=10) received daily i.p. injections of donepezil and the
control group (C; n=10) daily injections of saline.
Drug
For 3 weeks prior to the behavioral testing, donepezil (Eisai
Inc.) was administered daily at a dosage of 0.5 mg/kg; then,
for the next 7 weeks it was administered daily at a dosage
of 0.2 mg/kg dissolved in 0.5 ml of 0.9% NaCl solution.
The same volume of saline, but without the drug, was
administered daily to the control animals. All injections
were administered at the end of the testing sessions to avoid
any acute drug effects. According to clinical (Rogers et al.
1998; Rogers and Friedhoff 1996) and experimental (Wise
et al. 2007; Ogura et al., 2000; Dong et al. 2005) studies, a
0.2 mg/kg dose of donepezil is sufficient to influence
repeated behavioral testing but not to elicit heavy side
effects. The initial dose of 0.5 mg/kg was chosen to
habituate the rats to a high drug dosage that would be
reduced during the behavioral testing phase.
Behavioral testing
As shown in Fig. 1, a battery of six tests was administered
in the following order: Morris water maze (MWM), to
analyze competence in building a spatial cognitive map and
in using navigational strategies; radial arm maze (RAM), to
analyze spatial reference and working memory; serial
learning task (SLT), to analyze cognitive flexibility; open
field (OF), to evaluate the ability to develop spatial and
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discriminative competence; elevated plus maze (EPM), to
assess anxiety levels; shuttle box (SB), to analyze active
avoidance learning.
Morris water maze (MWM)
The rats were placed in a circular white pool (diameter
140 cm) filled with 24°C water (60 cm deep), made opaque
by the addition of 2 l of milk. An escape platform (diameter
10 cm), submerged 2 cm below or elevated 2 cm above the
water level, was placed in the middle of one cardinal
quadrant, 30 cm from the pool walls. The rat was released
into the water from randomly varied starting points and was
allowed to swim around for 120 s to find the platform. Each
rat underwent two sessions of four trials per day, with a
4-h inter-session interval. When the rat reached the platform,
it was allowed to remain there for 30 s. In the first four
sessions, the platform was hidden in the northwest quadrant
(place I); in the next two sessions, the platform was visible in
the northeast quadrant (cue phase); in the final four sessions,
the platform was hidden in the northeast quadrant (place II;
Morris et al. 1982; Petrosini et al. 1996; Federico et al. 2006;
Leggio et al. 2006). This protocol allowed investigating
numerous components of spatial function. Place I analyzed
the sequence of navigational strategies (spatial procedural
learning) put into action to explore the pool and to find the
platform, as well as the ability to build a spatial map (spatial
memory) by using extra-maze cues to locate the hidden
platform. The cue phase analyzed the development of
stimulus–response (platform/reaching) associative learning
and employment of the procedural knowledge acquired
during place I. Finally, place II analyzed the ability to
remodel the spatial map by exploiting the intra-maze
information acquired in the cue phase in the presence of
already acquired procedural strategies and also provided
information about the plastic properties of spatial learning
processes.
The rats’ trajectories in the pool were monitored by a
video camera mounted on the ceiling. Video signals were
relayed to a monitor and to an image analyzer (Ethovision,
Noldus, Wageningen, the Netherlands).
The following behavioral parameters were considered in
analyzing the MWM performances: latencies to find the
platform, total distance swum in the entire pool, distance
traveled in a 20-cm peripheral annulus, heading angles (the
angle formed by the direction of the rat’s head when
leaving the pool edge and a straight line from the starting
location to the platform), and swimming velocity.
Radial arm maze (RAM)
The apparatus consisted of a central platform (diameter
30 cm) from which eight arms (12.5 cm wide×60 cm long)
radiated like the spokes of a wheel. A food well (5 cm
deep) was located at the end of each arm (Mandolesi et al.
2001). Prior to the habituation phase, the rats were food
restricted to decrease their weight by 20%.
Full-baited maze procedure In each session, all maze arms
were baitedwith a piece of Purina chow. The rat was placed on
the central platform and allowed to make eight correct visits,
16 (correct or incorrect) visits, or to explore the maze for
15 min. The animals were submitted to two sessions a day for
5 consecutive days. The inter-session interval was 4 h.
The following parameters were considered: total entries
(number of visits, either correct or incorrect), total errors
(number of re-visited arms), spatial span (longest sequence
of correctly visited arms), and percentage of 45° angles
(45° angles made in each session divided by the total
number of angles made × 100).
Forced-choice procedure Forty-eight hours after the end of
the above-described protocol, all animals were submitted to
the forced-choice paradigm. In the first phase, only four
arms (for example, arms 1, 3, 4, and 7) were opened and
baited and the remaining arms were closed. The baited arms
were separated by different angles to prevent the animal
from solving the problem by adopting a stereotyped pattern.
 
FLOW DIAGRAM
3rd w2nd w1st w
MWM RAM
F-b
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F-c
SLT OF EPM SB
0.5 mg/kg 0.2 mg/kg                    Donepezil
food deprivation
Fig. 1 Flow diagram of experimental procedures. After the first
3 weeks of 0.5 mg/kg donepezil administration, a battery of six tests,
namely, MWM Morris water maze, RAM radial arm maze (F-b full-
baited and F-c forced-choice procedures), SLT serial learning task, OF
open field, EPM elevated plus maze, SB shuttle box, was performed
with concomitant 0.2 mg/kg donepezil administration. All rats were
food deprived during RAM and SLT tests. Gray boxes indicate test-
free days
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The rat was allowed to explore the open arms. Then, it was
put in its cage for 60 s before being returned to the maze. In
the second phase, the rat was allowed free access to all
eight arms, but only the four previously closed arms were
baited. This task was repeated for 5 consecutive days with a
different configuration of arms closed each day to avoid a
fixed search pattern.
The parameters considered were working memory
errors, considered as re-entries into already visited arms.
In the second phase, this parameter was broken down
further into two error subtypes: across-phase errors, defined
as entries into an arm entered in the first phase; within-
phase errors, defined as re-entries into an arm visited earlier
in the same session.
Serial learning task (SLT)
The apparatus consisted of a white rectangular wooden box
(150×40×40 cm) subdivided into five compartments
(30 cm long) by four gray panels with two unidirectional
doors (height 10 cm, width 8 cm). Each door could be locked
using a pivot; therefore, if the animal pushed the door it opened
about 2 cm. The small split allowed the rat to introduce its
muzzle but prevented it from going through the door. This trick
allowed us to obtain proof that the animals were attempting to
open the “incorrect” door. The entire apparatus was closed
with a transparent Plexiglas cover. The final, rewarded
compartment was darkened using a black cover.
The rats continued to be food restricted. Following a
3-day pre-training session, they were submitted to one
testing session a day for 10 consecutive days. All daily
sessions included 12 trials. In each trial, the goal was to
reach the fifth compartment and collect the reward by going
through the open doors and making no attempt to force
open the closed ones. Each animal was given a sequence of
open doors that remained unchanged for all 12 trials of a
session but that changed every session; thus, each animal
was tested in ten different sequences.
In each of the 12 trials of a session, the following
parameters were analyzed: errors, i.e., the attempt to force
open the closed door (in each trial this parameter ranged from
4 to 0); correct choices, i.e., the longest sequence of correct
choices (in each trial this parameter ranged from 0 to 4);
perseverations, i.e., the number of errors made at the same
door in the 12 trials of a session. As the first session gave the
animal time to become accustomed to the actual testing
procedure, only the results of S2–S9 were considered.
Open field (OF)
The apparatus consisted of a circular container (diameter
140 cm) delimited by a 30-cm-high wall. Five objects were
present simultaneously in the open field: (1) a metal bar
with a conical base, (2) a plunger, (3) a long steel rod, (4) a
yellow rubber plug, and (5) a black cylinder with a plastic
cup turned upside down on top of it.
During session 1 (S1), each rat was allowed to move
freely in the empty open field and its baseline level of
activity was measured. During S2–S4 (habituation phase),
four objects were placed in a square arrangement in the
middle annulus of the arena and the fifth one was placed in
the central area. For S5 (spatial change, S5 and S6), the
spatial configuration was changed by moving objects 2 and
5 so that the initial square arrangement was changed to a
polygon-shaped configuration, without any central object.
During S7 (novelty), the configuration was modified by
substituting object 4 with a green plastic object shaped like
a half moon. Sessions lasted 6 min; inter-session intervals
were 3 min.
All testing was recorded by a video camera whose signal
was relayed to a monitor and to the previously described
image analyzer.
The parameters taken into account were total distance (in
meters) traveled in the arena, distances traveled in the
peripheral or central arena sectors, and time spent contact-
ing objects (contact was considered to have taken place
when the rat’s snout actually touched an object or when it
sniffed the object for at least 1 s).
Elevated plus maze (EPM)
The maze, which was raised 90 cm above the ground was
formed by a wooden structure in the shape of a cross with
four 50 cm×10 cm arms. The north and south arms were
open, but the east and west arms were enclosed by walls
36 cm high.
The following behavioral parameters were measured:
number of defecation boluses, total time spent in the open
and closed arms or on the platform, and frequency of
entries into the arms.
Shuttle box (SB)
An active avoidance shuttle box (Ugo Basile type 7532,
Comerio-Varese, Italy) with an electrifiable grid floor (steel
rods spaced 1.5 cm apart) was used (Molinari et al. 1997).
The area inside the box was divided into two compartments
by a ceiling-to-floor partition that had a 10-cm central
opening to allow the animals to cross from one side to the
other. Each compartment had a 15-W bulb mounted on the
ceiling. Each daily session consisted of 100 automatic
computerized deliveries of conditioned (light, 15 W, 10 s)
and unconditioned (foot shock, 0.2 mA, 10 s) stimuli.
Sessions were repeated for 5 consecutive days.
The following parameters were considered: frequency
and latency of avoidances (shuttle behavior occurring
Psychopharmacology
during light time), frequency and latency of escapes (shuttle
behavior occurring when the foot shock was on), frequency
of failures (remaining in the start compartment until the
shock was turned off), and inter-trial crossings (repeated
passing from one compartment to the other during the trial
regardless of the light or the foot shock).
Statistical analysis
Metric unit results were compared by one-, two-, or three-
way analyses of variance (ANOVAs) followed by post hoc
multiple comparisons using Duncan’s test. Differences were
considered significant at p<0.05.
Results
Morris water maze
As the sessions went by, all animals displayed a progressive
reduction of latencies in reaching the platform (Fig. 2a). A
two-way ANOVA (treatment × session) on latency values
revealed significant treatment (F(1,18)=4.1; p<0.05) and
session (F(9,162)=35.1; p<0.00001) effects. Interaction
was also significant (F(9,162)=2.14; p<0.02). As indicated
by post hoc comparisons, at the start of the MWM task
there were no significantly different latency values between
the two groups of animals. However, in the next two place I
sessions the treated animals displayed lower latencies than
the controls. Interestingly, a significant difference between
groups was also found in the first session of the cue phase,
where the treated animals reached the visible platform more
quickly than the controls. A two-way ANOVA (treatment ×
session) on the total distance swum in the pool to reach the
platform revealed no significant treatment effect (F(1,18)=
0.01; p n.s.), but the session effect was highly significant
(F(9,162)=27.33; p<0.00001; Fig. 2b). Interaction was
also significant (F(9,162)=3.24; p<0.001). The mean
velocity of the treated animals was 27.14 cm/s, and that
of the controls 22.7 cm/s (one-way ANOVA: F(1,18)=
15.07; p<0.001). A two-way ANOVA (treatment × session)
on velocity values revealed significant treatment (F(1,18)=
14.99; p<0.001) and session (F(9,162)=3.38; p<0.001)
effects. Interaction was also significant (F(9,162)=2.41;
p<0. 01). Post hoc comparisons revealed significant
increases in velocity values during the 2nd and 3rd sessions
of place I. Thus, the latency reduction seemed to be related
to differences in velocity rather than to total distances.
Interesting results were found when the distance traveled in
the peripheral annulus was analyzed. Although all animals
tended to reduce their percentage of peripheral swimming
progressively (F(9,162)=5.28; p<0.00001) as the sessions
went by, the treated animals swam in the peripheral sectors
significantly less than the controls (F(1,18)=46.5; p<
0.00001) throughout the task. Interaction was not signifi-
cant (F(9,162)=1.38; p n.s.; Fig. 2c).
To obtain information about the localizatory knowledge
on platform position gained by the animals as the sessions
went by, the heading angles were calculated. Once again,
the two experimental groups exhibited the same heading
angles at the beginning of the task; however, from the end
of place I the treated animals displayed more pointed
localizing behavior, which was maintained throughout the
task (Fig. 2d). A two-way ANOVA revealed significant
treatment (F(1,18)=6.41; p<0.02) and session (F(9,162)=
9.35; p<0.00001) effects. Interaction was not significant
(F(9,162)=1.75; p n.s.).
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Fig. 2 Effects of chronic donepezil treatment on the MWM perform-
ances of healthy young rats. Mean escape latencies to reach the
platform (a), total distance swum in the whole arena (b), percentage of
distance swum in a 20-cm peripheral annulus (c), and heading angles
(d) displayed by the two experimental groups are depicted. In this and
in the following figures, D donepezil-treated animals, C control
animals. Asterisks indicate post hoc comparisons (Duncan’s test)
between groups. *p<0.05, ***p<0.001. Vertical bars indicate SEM
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Radial arm maze
Full-baited procedure
As the sessions went by, all animals decreased their entries
and errors significantly (entries: F(9,162)=6.18; p<0.0001;
errors: F(9,162)=7.18; p<0.0001); however, the treated
animals made significantly fewer entries and errors than the
controls (entries: F(1,18)=6.41; p<0.02; errors: F(1,18)=
7.12; p<0.02). Neither interaction was significant (entries:
F(9,162)=1.4; p n.s.; errors: F(9,162)=1.5; p n.s.; Fig. 3a).
No effect of treatment on the spatial span was found, as
revealed by a two-way ANOVA (treatment: F(1,18)=0.05;
p n.s.; session: F(9,162)=4.15; p<0.0001; interaction: F
(9,162)=0.47; p n.s.).
As illustrated in Fig. 3b, the percentages of 45° angles
followed different time courses in the two experimental
groups. Although their starting values were similar to those
of the controls, the treated animals made higher percentages
of 45° angles from the 5th session on and, in the last two
sessions, displayed the same 45° angle percentages as the
controls. A two-way ANOVA revealed significant treatment
(F(1,18)=10.68; p<0.04) and session (F(9,162)=2.97; p<
0.01) effects. Interaction was also significant (F(9,162)=
2.14; p<0.03). A correlation analysis between 45° angles
and errors of the two experimental groups in the ten RAM
sessions was performed (Table 1). In treated animals,
Pearson’s r evolved from very low positive values to high
negative values. This pattern was different from that of the
controls whose Pearson’s r values were low and negative in
the first and last sessions and positive in the middle
sessions. These findings show a different use of mnesic
and procedural competences in the two experimental
groups.
Forced-choice procedure
The treated group, which already performed better than the
controls in the first phase (two-way ANOVA: treatment: F
(1,18)=10.69, p<0.01; sessions: F(4,72)=8.22, p<0.001;
interaction: F(4,72)=4.12, p<0.01), made significantly
fewer errors even in the second phase (two-way ANOVA:
treatment: F(1,18)=4.34, p=0.05; sessions: F(4,72)=4.85,
p<0.01; interaction: F(4,72)=3.90, p<0.01; Fig. 3c).
An additional error analysis revealed that treated animals
made fewer across-phase errors than controls (two-way
ANOVA: treatment: F(1,18)=6.71; p<0.02; session: F
(4,72)=3.82; p<0.01; interaction: F(4,72)=4.98; p<
0.001). However, no difference was found between groups
for within-phase errors (Fig. 3c).
Serial learning task
A significant difference in the total number of errors made
by the two groups was revealed by one-way ANOVA (F
(1,18)=7.79; p<0.01; Fig. 4a). The treated group showed
fewer perseverations than the controls (one-way ANOVA:
F(1,18)=4.33; p<0.05; Fig. 4b). The longest sequences of
correct choices, which were made in the 2nd and the 10th
session, were compared by means of a two-way ANOVA
(treatment × session). This analysis revealed significant
treatment (F(1,18)=21.4; p<0.001) and session (F(1,18)=
145.59; p<0.00001) effects. Interaction was also significant
(F(1,18)=22.03; p<0.001). In both groups, post hoc
comparisons indicated a significant lengthening of the
sequence of correct choices from the 2nd to the 10th
sessions (p<0.0001); however, the treated animals per-
formed better in both sessions (Fig. 4c).
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Fig. 3 Effects of chronic donepezil treatment on the RAM perform-
ances of healthy young rats. Total errors (a) and 45° angles (b)
displayed by the two experimental groups in the full-baited procedure
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The errors made by both experimental groups in the 12
trials of the 2nd, 5th, and 10th sessions were compared by
means of a three-way ANOVA (treatment × session × trial),
which revealed significant treatment (F(1,18)=13.61; p<
0.001), session (F(2,36)=59.20; p<0.00001) and trial (F
(11,198)=22.57; p<0.00001) effects. The interaction treat-
ment × trial was significant (F(11,198)=1.95; p<0.03), but
the interaction treatment × session was not (F(2,36)=0.79;
p n.s.). The among-factor interaction was also significant (F
(22,396)=1.71; p<0.02). Thus, the treated animals im-
proved their performances and progressively reduced their
errors more than the controls within the same session (the
performances of the 12th trial were typically better than
those of the first trial) and throughout the task (the
performances of the 10th session were better than those of
the first session; Fig. 5).
Table 1 Correlation between 45°angles and errors made by the experimental groups during RAM full-baited procedure
Group Session
I II III IV V VI VII VIII IX X
D 0.06 0.36 −0.11 −0.05 −0.14 −0.73 −0.62 −0.56 −0.61 −0.32
C −0.45 −0.55 −0.49 0.39 0.26 0.47 0.13 −0.16 −0.24 −0.51
D Donepezil-treated group, C control group
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Fig. 4 Effects of chronic donepezil treatment on the SLT perform-
ances of healthy young rats. Mean errors (a), perseverations (b), and
the longest sequences of correct choices displayed by the two
experimental groups are depicted. Asterisks indicate post hoc
comparisons (Duncan’s test) between groups. *p<0.05, **p<0.01.
Vertical bars indicate SEM
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Fig. 5 Effects of chronic donepezil treatment on the SLT perform-
ances of healthy young rats. Errors made by the two experimental
groups in the 12 trials of the 2nd, 5th, and 10th sessions are depicted.
Vertical bars indicate SEM
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Open field
The absence of significant differences in the number of
defecation boluses (F(1,18)=0.29; p n.s.) indicated that all
animals exhibited a comparable level of anxiety. Only the
session effect was significant (F(6,108)=17.20; p<
0.00001), given the already scanty number of boluses
collapsed as the task went by. Further, motionless time
during the task did not significantly differ between the two
groups (F(1,18)=1.02; p n.s.). Only the session effect was
significant, because of the prolonged time spent motionless,
as the sessions went by (F(6,108)=14.41; p<0.00001). No
significant differences in number of rearings were observed
(two-way ANOVA: treatment: F(1,18)=1.52; p n.s.; ses-
sion: F(6,108)=10.27; p<0.00001; interaction: F(6,108)=
0.44; p n.s.). Regarding the distance traveled within the
arena during the seven sessions, a two-way ANOVA
revealed that, while the treatment effect (F(1,18)=1.50;
p n.s.) was not significant, the session effect (F(6,108)=
20.04; p<0.00001) and the interaction (F(6,108)=2.45; p<
0.03) were significant (Fig. 6a). As revealed by post hoc
comparisons on distances traveled in the single sessions by
the two groups, in S1, S2, and S7, the treated animals
traveled longer distances than the controls. To evaluate
which sectors (peripheral or central) of the arena were
explored most, one-way ANOVAs on distances traveled in
S1, S2, and S7 revealed that the central sectors (containing the
objects in S2 and S7) were significantly more explored by the
treated animals in S2 (F(1,18)=4.43; p<0.05) and S7 (F
(1,18)=4.18; p<0.05). In S1, no difference between groups
(F(1,18)=1.3; p n.s.) in traveling the central sectors was
found (treated group: x : 20:23 2:71; x : 17:49 5:39).
When objects were present, all animals showed habitu-
ation (Fig. 6b). However, the habituation features were
influenced by the treatment (F(1,18)=5.14; p<0.04),
because in S2 the treated animals tended to maintain
contact with the objects longer than the controls. Session
effect (F(2,36)=39.00; p<0.001) and interaction were also
significant (F(2,36)=7.53; p<0.01).
As revealed by a three-way ANOVA (treatment ×
session × object), during the spatial change (S5 and S6)
all rats explored the displaced objects more than the non-
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Fig. 6 Effects of chronic donepezil treatment on the OF performances
of healthy young rats. Total distance traveled in the arena throughout
the seven sessions of the task (a), mean contact time with objects
during habituation phase (S2–S4; b), spatial change (S5–S6; c), and
novelty (S7; d) of the two experimental groups are depicted. Asterisks
indicate post hoc comparisons (Duncan’s test) between groups. *p<
0.05, **p<0.01, ***p<0.001. Vertical bars indicate SEM. In C, NDO
non-displaced objects, DO displaced objects. In D, FO familiar
objects, NO novel object
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displaced ones (F(1,18)=54.1; p<0.0001); thus, the treat-
ment effect on the spatial change was not significant (F
(1,12)=1.63; p n.s.). Post hoc comparisons performed on
the significant second-order interaction (F(1,18)=5.69; p<
0.03) provided interesting results. In S5, the treated animals
contacted the displaced objects significantly (p<0.0002)
longer than the controls and they continued to display
significantly (p<0.004) longer contact with the displaced
objects in S6. Note that this “strategy” of durable context
exploration by the treated animals was not shared by the
controls, which showed no difference in contact times
between displaced and not-displaced objects in S6 (Fig. 6c).
During novelty, in both groups of animals the contact
time with the familiar objects was very brief, but the treated
animals contacted the novel object longer than the controls.
A two-way ANOVA (treatment × object) revealed signifi-
cant treatment (F(1,18)=10.38; p<0.005) and object (F
(1,18)=37.93; p<0.00001) effects. Interaction was also
significant (F(1,18)=8.65; p<0.01; Fig. 6d).
Elevated plus maze
While the controls spent more time in the closed arms, the
treated animals, which did not exhibit the normal open arm
avoidance, spent a similar amount of time in both kinds of
arms, as illustrated in Fig. 7. In fact, when the differences in
the time spent in the closed vs. open arms by the two
experimental groups were analyzed by means of a one-way
ANOVA, a significant treatment effect was found (F(1,18)=
4.52; p<0.05). Once more, no significant difference in
defecation boluses was found between groups. To verify
the presence of hyperactive behaviors, the frequencies of
entries in the arms were analyzed. As no significant
treatment effect was evident in the frequency of entries into
the arms (F(1,18)=0.10; p n.s.), hyperactive effects of
donepezil can be excluded.
Shuttle box
Both groups exhibited an almost complete absence of
escape failures D : x ¼ 4:4 2:7; C : x ¼ 6:2 3:8ð Þ and
inter-trial crossings D : x ¼ 1:1 0:4; C : x ¼ 2:2 0:7ð Þ.
The progressive decrease in escape frequencies was
associated with a parallel increase in avoidances during
the five testing sessions. Two-way ANOVAs (treatment ×
session) failed to reveal significant treatment effects in
escape and avoidance frequencies, while the session effect
was highly significant for both responses (escapes: treat-
ment F(1,18)=0.29; p n.s.; sessions F(4,72)=23.68; p<
0.00001; interaction F(4,72)=0.3; p n.s.; avoidances:
treatment F(1,18)=0.67; p n.s.; sessions F(4,72)=20.31;
p<0.00001; interaction F(4,72)=1.17; p n.s.). The same
statistical pattern was found when the latencies of avoi-
dances and escapes were examined. This latter result seems
to be linked to intrinsic features of the active avoidance
task, in which simple conditioning (light/shock) was
required. In fact, both groups of animals obtained good
learning performances.
Discussion
Few studies in healthy humans have addressed changes in
cognitive function provoked by chronic administration of
AChE-Is in the presence of unaltered cholinergic transmis-
sion (Ernst et al., 2001; Yesavage et al. 2002; Kumari et al.
2003; Gron et al. 2005), and there are even fewer studies in
animals (Barnes et al., 2000; Dong et al. 2005; Hernandez
et al. 2006). However, it seems important to assess the
cognitive performances of healthy subjects treated chroni-
cally with AChE-Is. In fact, even in healthy subjects it is
important to analyze the difference between long-term
administration and acute single-bolus injection of AChE-
Is, because it is crucial that a drug which is effective in the
acute form also be effective with repeated administrations.
Furthermore, manipulation of cholinergic neurotransmis-
sion in subjects in which cholinergic functioning is not
altered by pharmacological agents or physiological aging
may shed light on the effects of the so-called cognitive
enhancers, or, as Rose (2002) termed them, the “smart
drugs”.
To verify whether specific cognitive functions (and in
the affirmative case, which ones) were influenced by
sustained cholinergic enhancement in healthy rats, we used
a large battery of tests that tapped very different functions
including spatial or non-spatial, associative or discrimina-
tive, mnesic or attentive, and procedural or mapping
competences.
Cholinergic enhancement positively influenced functions
that require a significant working memory load; it speeded
Fig. 7 Effects of chronic donepezil treatment on the EPM perform-
ances of healthy young rats. Time spent in open arms (OA) and closed
arms (CA) by the two experimental groups is depicted. The asterisk
indicates the post hoc comparison (Duncan’s test) between groups.
*p<0.05. Vertical bars indicate SEM
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up the acquisition of procedural competences, ameliorated
functions linked to declarative (localizatory) memory,
augmented responsiveness to the context, and reduced
anxiety levels. Conversely, the treatment did not affect
short-term spatial memory storage and did not modify
motivational levels or influence associative learning. Spe-
cifically, at the start of the MWM task the treated animals
exhibited the same latencies as the controls but quickly
acquired significantly lower latencies, suggesting improved
mnesic and mapping abilities (hidden platform) as well as
increased attention to contextual cues (visible platform;
Petrosini et al. 1996; Federico et al. 2006; Leggio et al.
2006). Moreover, they exhibited reduced peripheral swim-
ming throughout the testing. In general, the treated animals
showed improved spatial learning and increased motor
activity, as indicated by their higher swimming velocity.
Furthermore, they acquired more pointed (although not
necessarily more efficient) navigational strategies, as
indicated by their narrow heading angles. The present
findings are in agreement with Hernandez et al. (2006) who
reported that aged rats chronically treated with donepezil
displayed superior performances in reaching the hidden
MWM platform. Further, it has been found that the spatial
deficits induced by bilateral lesions of entorhinal cortex are
partially antagonized by acute donepezil treatment (Spowart-
Manning and van der Staay 2005).
In the full-baited RAM procedure, the treated group
made significantly fewer errors than the control group.
Successful performance on the RAM task requires working
memory and mapping abilities as well as efficient proce-
dural competences. In fact, to avoid repeated entries in
already visited arms the subjects have to remember the arm
just visited, represent the maze in a cognitive spatial map,
and/or use efficient procedural strategies. A general
evaluation of the behavior of both groups indicates that in
the first sessions the controls reduced their errors by using
(even if only partially) procedural competences, while in
the middle sessions they mainly employed working
memory abilities. Conversely, in the middle sessions the
treated rats primarily exploited procedural competences and
reduced working memory load, as indicated by their
progressively correlated use of efficient strategies (45°
angles) to diminish errors (Table 1). Given their high 45°
angle percentage, it was necessary to distinguish procedural
from working memory requirements, which the forced-
choice procedure allowed. In this procedure, the treated
animals’ errors were significantly reduced. Thus, it can be
suggested that, depending on the context, the treated
animals were able to reorganize their strategies and shift
from using spatial procedures to applying mnesic compe-
tences. The present RAM data fit with the improved
working memory performances displayed by normal mice
treated acutely with donepezil and tested in a T-maze
continuous alternation task (Spowart-Manning and van der
Staay 2004). Accordingly, in normal rats acute donepezil
treatment reduced errors in a delay RAM procedure (Wise
et al. 2007). Evidently, the beneficial effects of acute
donepezil treatment on working memory competences were
maintained in the case of chronic treatment.
In the OF task, cholinergic treatment increased explor-
ative tendencies, as indicated by the longer distances
traveled by the treated animals in S1, S2, and S7. Note
that the treated animals foraged the arena and, especially,
visited the middle area containing the objects. Overall,
these findings suggest that the treated animals were more
responsive to the context. In fact, they were more active
when they faced a new context (in S1, a new empty open
field) or when it dramatically changed (in S2, an open field
with five new objects; in S7, the introduction of an
unknown object). The treated animals’ greater responsive-
ness to the context was revealed by their prolonged contact
times with the displaced or novel objects in S5–S6 and S7.
Once again, this result is in line with acute donepezil effects
in spatial and visual memory tasks in the presence of
scopolamine-induced cholinergic hypofunction (Kirkby et
al. 1996; Rupniak et al. 1997; Poorheidari et al. 1998).
Accordingly, in intact rats acute donepezil administration
improved object recognition memory (Prickaerts et al.
2005).
The cholinergic treatment does not seem to elicit
hyperactive tendencies. In fact, in OF the treated animals
spent their time contacting the objects and did not forage
around the arena (Fig. 6); in RAM they displayed a low
number of entries; in EPM they exhibited the same entry
frequencies as the controls; in SB they did not show
augmented activity, as indicated by inter-trial crossings.
Interestingly, in EPM the treated animals spent the same
amount of time in the closed arms as in the open ones,
indicating they had low levels of anxiety. This finding fits
with the benefits of donepezil in treating the behavioral
symptoms of dementia (Levy et al. 1999; Gauthier et al.
2002a, b; Palmer 2002). As anxiety levels can affect
learning and memory functions, it cannot be excluded that
a component linked to the decreased anxiety exhibited by
the treated animals could have influenced (even if only
partially) their performances.
Overall, the present results show that treated animals
exhibit accelerated acquisition and enhancement of both
working and long-term memory together with rapid
transition from one competence to another (for example,
from procedural to mnesic competence). These better
performances could be linked to a more complex mnesic
representation, with stronger connections among cues, and
to quick learning of procedural competences, driving
explorative strategies more confidently. Overall, the treated
animals seemed to process information more efficiently and
Psychopharmacology
to employ adaptive strategies more quickly than the
controls. In other words, cognitive flexibility—a process
as fundamental as memory in information processing—
appeared to be another factor favorably influenced by
cholinergic treatment. In fact, it was to be expected that the
treated animals would also show improved performances
on tasks such as serial learning and, indeed, this was the
case. In fact, in SLT treated animals demonstrated increas-
ing efficiency in learning the repeated changes in the same
problem. They displayed fewer errors than the controls and
progressively reduced their errors both within the same
session and throughout the sessions. Accordingly, the
treated animals exhibited longer sequences of correct
choices and reduced perseverations compared with the
controls. While the daily task of detecting and remembering
the correct sequence of choices primarily tapped mnesic
functions, the daily task of facing different and unpredict-
able sequences of choices primarily tapped flexibility
behaviors. The present data indicate that cholinergic
enhancement made it possible for the animals to learn
either the correct sequence of choices or how to efficiently
switch among changing response rules.
The possibility that the improvements displayed by the
treated animals were due to changes in motivation rather
than to specific effects on learning and memory processes
was considered. However, the cholinergic manipulation did
not appear to affect motivational components by modifying
the salience of the reward/punishment. In fact, all of the
animals reached and promptly climbed onto the MWM
platform; they always consumed the food pellets in RAM
and SLT, and showed comparable response latencies
(avoidances and escapes) in SB.
In conclusion, the present data highlight the positive
effects of chronic donepezil treatment on mnesic abilities as
well as on procedural, discriminative, and adaptive func-
tions. There is some disagreement about how the choliner-
gic system promotes memory performances. According to
some authors, mnesic improvement is driven directly by
ACh (Gold 2003), while according to others it is indirectly
mediated by enhancement of attentional functions (Everitt
and Robbins 1997; Gill et al. 2000). Still others argue that
ACh affects interactions between mnesic and attentive
functions (Sarter et al. 2003; Parent and Baxter 2004).
Specifically, cholinergic activation is considered a prereq-
uisite of sustained attention (Sarter et al. 2001) which, in
turn, appears to be a prerequisite of information acquisition,
recall, and appropriate responses to environmental stimuli
(Pepeu and Giovannini 2004). This approach was supported
by neuroimaging experiments on volunteers subjected to a
visual working memory task. It showed that physostigmine-
induced cholinergic enhancement improved memory per-
formance by augmenting the selectivity of perceptual
processing during encoding (Furey et al. 2000). Following
this line, it is not surprising that the treated animals
exhibited enhanced mnesic capacities, as shown by MWM
and RAM results, and superior discriminative abilities, as
shown by OF results, although the two components may be
difficult to disentangle.
It has been suggested that mechanisms other than
enhancement of cholinergic functioning may also be
responsible for donepezil efficacy in improving cognitive
functions (Narahashi et al. 2004). In addition to its effects
on ACh, donepezil is reported to increase levels of
norepinephrine, dopamine, and serotonin (Giacobini et al
1996; Zhang et al. 2004; Hatip-al-Khatib et al. 2005; Liang
and Tang 2006; Shearman et al 2006), and to augment the
activity of the NMDA system (Moriguchi et al 2005).
However, as donepezil interactions with non-cholinergic
neurotrasmettitorial systems have only been investigated in
a few studies, using heterogeneous methodologies, different
drug dosages, and evaluating cortical or subcortical regions, it
is difficult to draw any final conclusions. On the other hand,
the cholinergic projections are so widely diffused (Levin and
Simon 1998; Pepeu and Giovannini 2004) that an interaction
with other neurotransmitter systems is quite feasible.
Taken together, the present findings reveal the faceted
action of donepezil on cognitive functions in the presence
of unaltered cholinergic neurotransmission, suggesting that
AChE-Is may be beneficial even in the case of specific
cholinergic hypofunctions, targeting some symptoms more
than others. This specific action of donepezil on cognitive
function may be an expression of the not yet fully
understood role of ACh in cognition.
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